Ezabenlimab
- Generic Name
- Ezabenlimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2249882-54-8
- Unique Ingredient Identifier
- 5V1UI86573
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
Phase 1
Active, not recruiting
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- Drug: BI 765063Drug: EzabenlimabDrug: CetuximabOther: Investigator´s Choice ChemotherapyDrug: BI 836880
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT05249426
- Locations
- 🇫🇷
CTR Leon Berard, Lyon, France
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
🇫🇷CTR Georges-François Leclerc, Dijon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath